Physician profile
Roy B Kellum
NPI 1326181421
$2,016.67
in general payments reported to CMS, 2019-2025
26 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $133 · 2021: $638 · 2022: $125 · 2023: $360 · 2024: $369 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $605.46 | 2019-2023 | |
| Stryker Corporation | $172.84 | 2024 | Infinity Adaptis |
| Amgen INC. | $172.12 | 2019-2021 | |
| Astellas Pharma US INC | $152.58 | 2020-2025 | Veozah |
| Gynesonics, INC. | $143.53 | 2021 | |
| Hologic Sales and Service, LLC | $115.69 | 2021-2025 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Daiichi Sankyo INC. | $92.84 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $88.45 | 2023-2025 | |
| Pfizer INC. | $54.73 | 2021-2023 | |
| Organon LLC | $54.69 | 2024-2025 | Nexplanon |
| Pacira Pharmaceuticals Incorporated | $48.35 | 2022-2023 | Zilretta, Exparel, Iovera |
| Horizon Therapeutics Plc | $47.18 | 2019-2020 | |
| Lilly USA, LLC | $30.50 | 2025 | Zepbound, Mounjaro |
| Convatec INC. | $29.01 | 2025 | |
| Shield Therapeutics INC | $28.38 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $27.25 | 2019-2020 | |
| Channel Medsystems, INC. | $25.37 | 2024-2025 | |
| Innovation Technologies INC | $19.90 | 2024 | Irrisept |
| Biohaven Pharmaceutical Holding Company LTD. | $17.53 | 2022 | |
| Sumitomo Pharma America, INC. | $16.73 | 2025 | Gemtesa |
| Smith+Nephew, INC. | $14.39 | 2024 | Pico 7 |
| Revvity, INC. | $14.38 | 2023 | |
| Therapeuticsmd, INC. | $13.68 | 2021 | |
| Novo Nordisk INC | $13.35 | 2024 | Saxenda, Wegovy |
| Avanos Medical | $12.42 | 2019 | |
| Evofem Biosciences, INC. | $5.32 | 2025 | Phexxi, Solosec, Phexx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Kellum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.